In a subsequent set of experiments, we show that the addition of PI3K inhibitors to the combination of vemurafenib with trastuzumab or cetuximab induces a partial response of Braf-mutated tumours and a temporary stabilisation followed by a slower progression of Ras/Braf-wt and Kras-mutated tumours. Here, KRAS is linked to neoplasm.